latin-america-header

LATIN AMERICA

We entered the Latin American market in 2008 and initially established a presence in Brazil, Mexico and Venezuela. We have expanded our coverage in this region and now also have a presence in Colombia, Chile, Ecuador, Costa Rica, Peru and Argentina and offer a comprehensive product range that encompasses branded prescription and OTC products as well as infant nutritionals.Our Vallejo site in Mexico has the capability to manufacture infant nutritionals as well as pharmaceutical solids, semisolids and liquids.

Key Countries

Brazil
Chile
Colombia
Ecuador
Mexico

Contribution to Group revenue

lat-am-contrib-1

Revenue contribution - by therapeutic category

latin-america-1
  • The Spanish Latin American private pharmaceutical sector grew 8,9% to USD25,2 billion for the year to 30 June 2018 as per IMS.
  • The Brazilian private pharmaceutical sector grew 5,4% and was valued by IMS at USD30,0 billion for the year to 30 June 2018.

Source: June 2018 IMS

STATISTICS

Number of products launched:

11

(2017: 26)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD424 million

3 – 5 years

USD298 million

Number of product recalls:

2

(2017: 1)

Average staff turnover:

22,8%

(2017: 29,5%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

latin-america-employees

Revenue – R’billion20182017 (CER)% change
Total4 2313 9916
Commercial Pharmaceuticals2 9292 57714
Regional Brands1 3061 11617
Anaesthetics76257133
Thrombosis7187(18)
High Potency & Cytotoxics790803(2)
Nutritionals1 2901 414(9)
Manufacturing – FDF12100

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture